Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus savolitinib after progression on first-line osimertinib in EGFRm+ MET+ NSCLC
2024-512564-58-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and savolitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Overall Response Rate (ORR) by investigator assessment. Planned start Aug 2024; status: authorised.
02
Drugs
osimertinibsavolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512564-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512564-58-00.